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Abstract Psoriasis is an inXammatory skin disorder that
is inherited as a multifactorial trait. Genetic analyses have
repeatedly identiWed a primary disease susceptibility locus
lying within the major histocompatibility complex (MHC),
on chromosome 6p21. A small number of non-MHC sus-
ceptibility loci have also been identiWed. These regions tend
to overlap with susceptibility intervals for Crohn’s disease
and atopic dermatitis, suggesting the possibility that genetic
variants aVecting inXammatory pathways may contribute to
the pathogenesis of multiple disorders. Here, we report a
genetic analysis of the interleukin 23 receptor gene
(IL23R), which was recently identiWed as a susceptibility
determinant for Crohn’s disease. We initially examined the
results of a whole-genome association scan, carried out on
318 cases and 288 controls. We observed a signiWcant
increase of a non-synonymous substitution (p.Arg381Gln)
among controls (P = 0.00036). We validated this Wnding by
extending our cohort to include a further 519 cases and 528
controls. In the overall sample, the frequency of the 381Gln
allele was 3.6% in cases and 7% in controls, yielding a P
value of 0.00014. Next, we examined genetic variation at
the IL12RB1, IL23A and IL12B genes, respectively, encod-
ing the second subunit of the IL23R receptor and the two
subunits of its ligand. This analysis identiWed independent
associations for IL12B SNPs rs10045431 (P value for the
extended dataset = 0.0001) and rs3212227 (P = 0.036).
Altogether, these Wndings indicate that genes participating
in IL23 signalling play a signiWcant role in the pathogenesis
of chronic epithelial inXammation.
Introduction
Psoriasis is a chronic skin disorder, characterized by the
inWltration of inXammatory eVector cells and cytokines into
the dermis and the epidermis (NickoloV and Nestle 2004;
Smith and Barker 2006). Familial recurrence of the disorder
is well established and psoriasis has long been considered a
multifactorial trait (Bowcock and Cookson 2004). Linkage
and association analyses have provided overwhelming
support for a major susceptibility locus, lying within the
major histocompatibility complex (MHC) on chromosome
6p21 (Capon et al. 2002). Conversely, the characterization
of non-MHC disease loci has been problematic, owing to
the small eVects of the underlying genetic variants.
Genome-wide scans have mapped no less than nine non-
MHC psoriasis susceptibility loci, but only a fraction of
these have been validated in independent cohorts (Capon
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et al. 2004b). High-resolution genetic analyses have identi-
Wed putative susceptibility alleles for the PSORS2 locus on
chromosome 17q25, but these Wndings have not been repli-
cated in follow-up studies (Capon et al. 2004a; Helms et al.
2003; HuVmeier et al. 2005; Stuart et al. 2006).
Non-MHC psoriasis susceptibility loci tend to overlap
with disease regions for other inXammatory disorders, espe-
cially atopic dermatitis (Cookson et al. 2001) and inXam-
matory bowel disease (Lee et al. 2000; Nair et al. 1997).
These observations suggest that genetic variants aVecting
inXammatory pathways may contribute to the pathogenesis
of clinically distinct disorders. This hypothesis is supported
by the observation of multiple disease association for genes
such as PTPN22 (Bottini et al. 2006) and CTLA4 (Ueda
et al. 2003), which are involved in inXammatory and auto-
immune responses.
Here, we report a detailed analysis of the interleukin-23
receptor (IL23R) gene locus, which has been recently identi-
Wed as a susceptibility gene for Crohn’s disease (Duerr et al.
2006). We describe a signiWcant increase for the IL23R
p.Arg381Gln variant among controls, a Wnding that we docu-
mented in two independently ascertained datasets. We also
report a signiWcant association for SNPs rs10045431 and
rs3212227, mapping to the IL12B gene, which encodes one
of the subunits of the IL23 receptor ligand.
Methods
Subjects
The whole-genome association (WGA) scan was carried
out on 318 British patients of North-European descent (208
males and 110 females; average age 52.1 years; range 23–
86 years) and 288 ethnically matched and unrelated con-
trols (144 males and 144 females; age not known). All
patients were recruited at St John’s Institute of Dermatol-
ogy (London, UK), following an examination by an expert
clinician (JNB). The control individuals were obtained
from the European Collection of Cell Cultures (ECACC;
http://www.ecacc.org.uk) Human Random Control Panel, a
cohort of healthy Caucasian blood donors whose parents
and grand-parents were born in the UK.
The replication sample included 519 British patients of
North-European descent (220 males and 299 females; aver-
age age 44.1 years; range 9–91 years) and 528 unrelated
controls (264 males and 264 females; all 49 years old). One
hundred and seventy one unrelated patients were sampled
from a previously described set of multiplex pedigrees
(Trembath et al. 1997). The remaining cases were recruited
at St John’s Institute of Dermatology and Glasgow Western
InWrmary. The 528 controls were part of the 1958 Birth
Cohort, a nationally representative dataset, which includes
individuals born in 1958, in England, Wales and Scotland
(Power and Elliott 2006). All patients and controls gave
their informed consent to use of their DNA for genetic epi-
demiological analyses. This study was approved by the
Guy’s and St Thomas’ Hospitals Ethics Committee of
Kings College, London.
Genotyping
The WGA scan was carried out on case and control DNA
pools, generated as previously described (Steer et al. 2007).
BrieXy, DNA was diluted to 50 ng/l based on Quanti-iT
Picogreen (Invitrogen) quantitation. The Picogreen analysis
was repeated on the diluted DNA and concentrations were
adjusted based on these results. This process was repeated
until all samples consistently measured 50 ng/l. Four repli-
cates of each pool were prepared and hybridized to Human-
Hap300 BeadChips (Illumina, San Diego, USA), according
to the manufacturer protocol. Estimates of allele frequencies
were obtained based on the hybridization intensities from
the two probes corresponding to each SNP allele. The Illu-
mina genotype calling algorithm was modiWed as previously
described (Steer et al. 2007), in order to maximize its accu-
racy in the context of pooled DNA genotyping.
In the follow up to the whole-genome scan, SNPs
rs1004819, rs7517847, rs10489629, rs2201841, rs7709212
and rs3212227 were typed using the Applied Biosystems
TaqMan assay, according to the manufacturer protocol.
SNPs p.Arg381Gln, rs1343151 and rs10045431 were geno-
typed by direct sequencing, using the BigDye 3.1 kit
(Applied Biosystems).
Direct sequencing
Primers were designed to amplify and sequence all IL23R
coding exons. PuriWed PCR products (primer sequences
and cycling conditions available on request) were
sequenced using the BigDye 3.1 kit and loaded on an ABI
3730xl automated sequencer (Applied Biosystems). Nucle-
otide changes were detected by visual inspection of chro-
matograms.
Statistical analyses
The diVerences in allele frequencies between case and con-
trol pools were expressed in terms of z-score, a statistic
incorporating errors due to imprecise measurements within
a DNA pool (Steer et al. 2007). Under the null hypothesis
of no association, the z-score is normally distributed, with a
mean value of zero and variance of one. Thus, the normal
distribution of the z statistic can be used to convert z-scores
into P values. For the purpose of this study, a z-score >2.4
(corresponding to P < 0.01) was considered as statistically
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signiWcant evidence for association. To assess the presence
of population stratiWcation within the WGA dataset, we
used software written in-house to analyze the observed z-
score distribution. Our program computes the value of k, a
multiplier that is used to adjust the z-score distribution, in
the presence of population stratiWcation. If cases and con-
trols are drawn from the same population, the z-score distri-
bution is very close to normality and the value of k
approaches 1.0 (e.g. when two pools collected from US
populations of North-European descent are compared,
k = 0.8). When cases and controls are drawn from ethni-
cally diVerent populations the z-score distribution is much
wider than expected and adjusting to normality requires a k
value that is somewhat diVerent from 1.0 (e.g. when pools
collected from North-Europeans and Ashkenazi Jews are
compared k = 0.15). Thus, the k value can be used to mea-
sure the presence of population stratiWcation, within a case-
control sample.
SNP haplotypes were derived from genotype data, using
PHASE 2.1 (Stephens and Scheet 2005). DiVerences in
allele and haplotype frequencies between individually
genotyped cases and controls were assessed using a 2 test
with one degree of freedom. The resulting P values were
corrected for the number of single markers (n = 9) and SNP
haplotypes (n = 4) that were independently tested. Geno-
type-conditioned analyses of IL12B markers were carried
out using the UNPHASED software, which implements a
test of equality of odd ratios for haplotypes that are identi-
cal at a conditioning locus (Dudbridge 2003).
Results
IL23R association analysis
In the initial phase of this study, we assessed the presence
of association at the IL23R locus by examining the raw data
from a stage I whole-genome association (WGA) scan, car-
ried out on pools of case (n = 318) and control (n = 288)
DNAs. The scan generated genotypes for 99% of the analy-
sed markers (n = 313,830 SNPs). The distribution of the
resulting z-scores was close to normality, matching the pat-
tern expected for two samples drawn from the same popula-
tion (k = 0.81). Importantly, this demonstrates the absence
of stratiWcation within the WGA case-control sample.
As expected, the most signiWcant association scores gen-
erated by the scan corresponded to MHC markers. The
highest ranking SNP was rs3134792 (z = 6.08;
P = 3.77 £ 10¡9), mapping centromeric to HLA-C. In the
IL23R region, the scan generated allele frequencies for 17
tag SNPs. We observed evidence for disease association for
two markers: rs11465804 in intron 8 (z = 3.1; P = 0.0009;
rank 722) and rs11209026 in exon 9 (z = 2.9; P = 0.002;
rank 1,311). Of note, rs11209026 is a non-synonymous SNP,
resulting in an Arg to Gln substitution (p.Arg381Gln).
To validate the association with IL23R markers, we indi-
vidually genotyped the case and control samples from the
WGA pools for the p.Arg381Gln substitution and Wve neigh-
bouring SNPs (rs1004819, rs7517847, rs10489629,
rs2201841, rs1343151). The disease associated SNP in intron
8 (rs11465804) was not further genotyped, since we found
that it is in high linkage disequilibrium with p.Arg381Gln
(D = 1; r2 = 0.9). Individual genotyping of case and control
samples showed that all examined markers were in Hardy–
Weinberg equilibrium (P > 0.05). Genetic analyses con-
Wrmed the association with the p.Arg381Gln substitution,
with the Gln allele showing a signiWcant increase among
control subjects (2 = 16.8; after correction for multiple test-
ing, Pc = 0.00036). None of the neighbouring SNPs showed
any evidence for disease association (Table 1).
The association with the p.Arg381Gln variant was sub-
sequently validated by expanding our dataset to include a
further 519 cases and 528 controls. In the combined sam-
ple, including a total of 837 cases and 816 controls, the
association with p.Arg381Gln yielded a Pc value of
0.00014 (OR 0.49; 95% CI 0.35–0.68).
To investigate the possibility that the association may be
secondary to linkage disequilibrium with other IL23R
Table 1 Association analysis 
of IL23R SNPs Pools z-score Minor allele frequency (allele counts) Odd ratio Pc value
Individual cases Individual controls 
rs1004819 1.1 0.33 (204/610) 0.32 (184/572) 1.05 N/S
rs7517847 1.2 0.44 (282/636) 0.43 (248/574) 0.96 N/S
rs10489629 0.66 0.45 (277/620) 0.45 (254/570) 1.00 N/S
rs2201841 0.65 0.35 (218/624) 0.32 (186/574) 1.10 N/S
rs1343151 2.0 0.34 (199/624) 0.33 (187/560) 0.93 N/S
p.Arg381Gln (WGA) 2.9 0.022 (14/620) 0.072 (41/562) 0.29 0.00036
p.Arg381Gln (replication) – 0.045 (45/996) 0.069 (72/1034) 0.63 0.17
p.Arg381Gln (combined) – 0.036 (59/1616) 0.07 (113/1596) 0.49 0.00014N/S not signiWcant
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variants, we re-sequenced the gene coding exons in 16
patients carrying the p.Arg381Gln substitution. This analy-
sis did not identify any coding variant that was in linkage
disequilibrium with the 381Gln allele.
Association analysis of the IL12RB1, IL23A and IL12B 
genes
Having established an association with an IL23R sequence
variant, we proceeded to investigate the other members of
the interleukin-23 receptor complex. We examined the
IL12RB1, IL23A and IL12B genes, which respectively
encode the second subunit of the IL23R receptor and the
two subunits of its ligand. The whole-genome association
scan provided us with allele frequencies for 29 tag SNPs
spanning these three genes (15 markers in IL12RB1, 2 in
IL23A and 12 in IL12B). None of the IL12RB1 and IL23A
markers showed any evidence for association. Conversely,
SNP rs7709212, which maps 6 kb upstream of the IL12B
coding region, yielded a z-score of 3.2 (P = 0.0007; rank
528). An examination of rs7709212 neighbouring markers
revealed a z-score of 3.5 for SNP rs10045431 (P = 0.0002;
rank 197), lying 60 kb upstream of IL12B. Individual geno-
typing of the entire data set conWrmed the presence of an
association with both rs7709212 (2 = 11.5; Pc = 0.006;
OR = 0.76; 95% CI 0.65–0.89) and rs10045431 (2 = 18.8;
Pc = 0.0001; OR = 1.41; 95% CI 1.21–1.64) (Table 2).
During the late stages of our study, Cargill et al. reported
a signiWcant association between psoriasis and IL12B
marker rs3212227 (Cargill et al. 2007). We analysed this
SNP in our dataset and were able to conWrm a marginal pro-
tective eVect for the rs3212227 locus (2 = 8.24;
Pc = 0.036; OR = 0.76; 95% CI 0.63–0.92).
All examined markers were found to be in Hardy–Wein-
berg equilibrium (P > 0.05).
We carried out haplotype-based association analyses,
using PHASE. This showed that the rs7709212 disease
associated allele is found on both risk-bearing and neutral
haplotypes (Table 3). Conversely the risk allele of marker
rs10045431 is only found on a single, disease-associated
haplotype (A T A). Likewise, the protective allele of SNP
rs3212227 is only found on one haplotype (C C C), whose
frequency is signiWcantly increased among controls
(Table 3).
In order to assess whether association at the rs10045431
locus was secondary to linkage disequilibrium with
rs3212227, we implemented genotype-conditioned analy-
ses, using the UNPHASED program. We observed signiW-
cantly diVerent odd ratios for the two rs10045431-
rs3212227 haplotypes that were identical at the rs3212227
locus (2 = 10.7; 2 df; P = 0.005), indicating that the
rs10045431 association cannot be ascribed to linkage dis-
equilibrium with rs3212227.
Statistical interaction analysis
In order to assess the presence of epistasis between IL23R
and IL12B disease associated alleles, we implemented a
case-only test for the detection of gene–gene interaction
(Yang et al. 1999). Under the null hypothesis of no epista-
sis, the genotype frequencies of unlinked markers are
expected to be independent from each other. We therefore
analysed the distribution of IL12B and IL23R patient geno-
types by carrying out 2 tests on 3 £ 3 contingency tables.
We observed non signiWcant 2 values for both the
rs10045431 versus p.Arg381Gln (2 = 3.71; 4 df; P = 0.43)
and rs3212227 vs. p.Arg381Gln comparison (2 = 2.91; 4
df; P = 0.57), indicating the absence of an epistatic interac-
tion between IL12B and IL23R disease associated SNPs.
Discussion
Interelukin-23 (IL-23) is an IL12-related cytokine, which
plays an important role in the regulation of cell-mediated
Table 2 Association analysis of IL12B SNPs
Pools 
z-score
Minor allele frequency (allele counts) Odd 
ratio
Combined 
Pc valueWGA cases WGA controls Replication cases Replication controls
rs7709212 3.2 0.30 (181/596) 0.32 (178/562) 0.26 (218/836) 0.35 (348/1004) 0.76 0.006
rs10045431 3.5 0.36 (198/556) 0.29 (161/558) 0.33 (327/978) 0.26 (247/954) 1.41 0.0001
rs3212227 n/a 0.15 (88/604) 0.18 (101/562) 0.16 (166/1034) 0.20 (198/982) 0.76 0.036
Table 3 Association analysis of IL12B haplotypes
Only haplotypes whose frequency was >1% in both cases and controls
were included in the Table; locus order: rs10045431, rs7709212,
rs3212227
Haplotype Frequency (counts) Pc 
value
Cases Controls
A T A 0.31 (525/1694) 0.25 (407/1630) 0.0004
C C C 0.14 (237/1694) 0.18 (293/1630) 0.007
C C A 0.12 (203/1694) 0.14 (228/1630) N/S
C T A 0.39 (661/1694) 0.39 (636/1630) N/S
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immune responses (Kastelein et al. 2007). IL-23 stimulates
the diVerentiation and proliferation of Th17 cells, a subset
of T helper cells that are critical mediators of inXammation
in several mouse models of autoimmune disease (Kikly
et al. 2006).
In this study, we used the raw data from a WGA scan to
show that variants in the genes for the IL-23 receptor
(IL23R) and the p40 IL-23 subunit (IL12B) are signiWcantly
associated with psoriasis. Our scan readily identiWed a very
strong association between the disease and MHC markers.
The association results at the IL23R and IL12B loci were
markedly less signiWcant, with ranks ranging from 197 to
1,311. These Wndings are consistent with the expectation
that non-MHC loci have a modest eVect on disease risk.
The observation of a signiWcant protective eVect for the
p.Arg381Gln IL23R variant is in agreement with the recent
Wndings by Duerr et al. who reported a similarly strong
eVect in multiple Crohn’s disease case-control datasets
(Duerr et al. 2006). In our study, we observed that the repli-
cation dataset generated a weaker association at the IL23R
locus (we found a P value of 0.019, which lost signiWcance
after correction for multiple testing), compared to the WGA
sample. Since the replication resource includes a large
number of patients that were sampled from pedigrees with
multiple aVected individuals, our results suggest that the
p.Arg381Gln substitution could have a weaker protective
eVect when high-penetrance susceptibility alleles are segre-
gating within a family.
During the late stages of this study, Cargill et al. also
documented a signiWcant association between psoriasis and
a number of SNPs mapping to the IL23R (p.Leu310Pro and
p.Arg381Gln) and IL12B genes (rs7709212, rs3212227 and
rs6887695) (Cargill et al. 2007). Such a high degree of
reproducibility is uncommon in the analysis of complex
traits and suggests that variation aVecting the IL23 receptor
complex plays a key role in the pathogenesis of chronic epi-
thelial inXammation.
We cannot exclude the possibility that the associations
that we observed may be secondary to linkage disequilib-
rium (LD) with as yet undiscovered causal alleles. Our
analysis of the IL12B locus identiWed independent associa-
tion signals for two non-coding SNPs, mapping to the
upstream region (rs10045431) and the 3 UTR of the gene
(rs3212227). Further investigations, including patient re-
sequencing and genotyping, will be necessary to identify
the speciWc variants underlying these associations.
Conversely, our patient re-sequencing eVort failed to
identify any IL23R coding variants that were in LD with the
protective allele p.Arg381Gln. Arg381, which is strongly
conserved among higher vertebrates, is located within the
binding domain for the JAK2 kinase, the Wrst mediator of
the IL23R signalling cascade (Parham et al. 2002). In this
context, it is tempting to speculate that p.Arg381Gln may
confer protection against inXammatory disease by inhibit-
ing downstream signalling.
Our analyses failed to detect any evidence of epistatic
interaction between IL12B and IL23R disease associated
alleles. A lack of epistasis between associated alleles of
substantial eVect has previously been reported for age-
related macular degeneration (Maller et al. 2006) and type
2 diabetes (Weedon et al. 2006), suggesting that gene–gene
interactions may have more subtle eVect on the pathogene-
sis of complex traits, than previously thought.
In conclusion, we have shown signiWcant association
between IL23R and IL12B variation and psoriasis. The ther-
apeutic relevance of our observations is highlighted by the
positive results of recent clinical trials where anti IL12-p40
antibodies have been used for the treatment of psoriasis
(Krueger et al. 2007). In this context, our association Wnd-
ings conWrm the pathogenic relevance of the IL23 signal-
ling cascade and provide further support for therapeutic
strategies targeting this pathway in the treatment of chronic
epithelial inXammation.
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